Stock CYTT CYTEIR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages Cyteir Therapeutics, Inc.

Equities

CYTT

US23284P1030

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cyteir Therapeutics, Inc. Estimates Common Stock Liquidation Distributions
Cyteir Therapeutics, Inc. Announces Resignation of Timothy Romberger from Board of Directors
Cyteir Therapeutics, Inc. Announces Board Changes
Cyteir Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cyteir Therapeutics' Ovarian Cancer Combination Treatment Candidate Shows 91% Overall Disease Control in Phase 1 Study
Cyteir Therapeutics, Inc. Presents Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer
Cyteir Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Top Midday Gainers
Cyteir Therapeutics, Inc. Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
Cyteir Therapeutics to Discontinue CYT-0851 Development, Plans Dissolution, Liquidation of Assets; Shares Rise Pre-Bell
Cyteir Therapeutics, Inc. Presents Results from A Phase 1 Study with CYT-0851
Cyteir Therapeutics, Inc. Announces Resignation of Adam Veness from His Position as General Counsel and Secretary, to Be Effective as of the Company’S Annual Meeting of Stockholders on June 14, 2023
Cyteir Therapeutics, Inc. Announces Resignation of Susan Molineaux from the Board of Directors
Athira Pharma Names Andrew Gengos CFO
Cyteir Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development
Cyteir Therapeutics, Inc. Approves Workforce Reduction by Approximately 70%
Cyteir Therapeutics, Inc. Announces Executive Changes
Cyteir Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Cyteir Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTT Stock
  4. News Cyteir Therapeutics, Inc.
  5. Other languages